<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832399</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-TYS-12-10409</org_study_id>
    <nct_id>NCT04832399</nct_id>
  </id_info>
  <brief_title>Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants</brief_title>
  <acronym>TYPIFI</acronym>
  <official_title>Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients - TYPIFI (Tysabri Patient Initiation After Failure of the Initial DMT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on&#xD;
      the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2013</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Disease-Free Status at Month 12</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Disease-Free Status at Month 12 in Comparison to the Previous Year</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized Relapse Rate at Month 12 in Comparison to the Previous Year</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Disease-Free Status at Months 24, 36 and 48</measure>
    <time_frame>Months 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease-free Status Every 6 Months</measure>
    <time_frame>Every 6 months (Up to 48 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sustained Expanded Disability Status Scale (EDSS) Score (24-week Sustained)</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
    <description>The EDSS is used to quantify disability due to symptoms of MS and to track changes in disability status over time. Scores range from 0 (normal neurological exam) to 10 (death due to multiple sclerosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI measures: T2, T1, T1 with Gadolinium (Gd)</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Impairment Using Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ability to Work and Productivity as Assessed by Work Productivity and Activity Impairment (WPAI) Questionnaire</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
    <description>The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages ranging from 0-100%, with higher numbers indicating greater impairment and less productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) Assessed Using Fatigue Severity Scale</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
    <description>The FSS is a self-assessment questionnaire that provides a score as a measurement of the severity of fatigue. It consists of 9 questions scored from 1 to 7. A low value (e.g., 1); indicates strong disagreement with the statement, whereas a high value (e.g., 7); indicates strong agreement. A total score of 36 or more suggests presence of fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL assessed using Multiple Sclerosis Functional Composite (MSFC) Test</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
    <description>MSFC has 2 component- timed 25-foot walk (T25FW) and 9-hole peg test (9HPT) [dominant and nondominant hands]. The MSFC Z-score is calculated by creating Z-scores for each component of the MSFC and averaging them to create an overall composite score. MSFC Z-score = (Z25-foot-walk + Z9HPT-2)/2, where Zj refers to Z-scores of component j. A Z-score represented the number of standard deviations participant's test result was higher (Z &gt;0) or lower (Z &lt;0) than the average test result (Z = 0) from the reference population. Higher scores indicate better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Assessed Using Beck Depression Inventory, 2nd Edition (BDI-II)</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
    <description>BDI-II Scale is a 21-item self-reported questionnaire which measures the existence and severity of symptoms of depression. Each of the 21 items on BDI-II tool represents a depressive symptom. The symptoms are each scored on a 4-point Likert scale of 0 to 3 (0=symptom is absent; 3=symptom is severe). Scores for each symptom are added up to obtain the total scores for all 21 items. Total score ranges from 0-63; of which 0-8 is considered no depression, 0-13 is minimal depression, 14-19 is mild depression, 20-28 is moderate depression and 29-63 is severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL Assessed Using Multiple Sclerosis Impact Scale (MSIS-29)</measure>
    <time_frame>Months 12, 24, 36 and 48</time_frame>
    <description>MSIS-29 is a brief self-administered instrument measuring physical (20 items) and psychological (9 items) impact of Multiple Sclerosis (MS). Each of the 29 items on MSIS-29 tool is a question that ask for participants views about the impact of MS on their day to day lives. Each item is scored on 1 to 5 (1=Not at all; 5=Extremely).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Natalizumab</arm_group_label>
    <description>Natalizumab 300 mg is administered by intravenous infusion once every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Natalizumab</intervention_name>
    <description>As described in the treatment arm.</description>
    <arm_group_label>Natalizumab</arm_group_label>
    <other_name>Tysabri</other_name>
    <other_name>BG00002</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with relapsing remitting multiple sclerosis (RRMS) that have been&#xD;
        prescribed natalizumab under standard clinical care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of Relapsing Remitting Multiple Sclerosis (McDonald 2010&#xD;
             Criteria).&#xD;
&#xD;
          -  EDSS â‰¤ 3.0.&#xD;
&#xD;
          -  Must fulfill Tysabri indication (relapse and MRI criteria).&#xD;
&#xD;
          -  Decision to start treatment with Natalizumab must precede enrollment.&#xD;
&#xD;
          -  Up to four natalizumab infusions.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any prior treatment with Natalizumab.&#xD;
&#xD;
          -  Prior imunossupressive treatment (Mitoxantrone, Azathioprine, Methotrexate,&#xD;
             Cyclophosphamide, Mycophenolate, Cladribine, Rituximab).&#xD;
&#xD;
          -  Contraindications to treatment with Natalizumab.&#xD;
&#xD;
          -  History of Progressive Multifocal Leukoencephalopathy (PML) or other opportunistic&#xD;
             infections, or an increased risk for such infections.&#xD;
&#xD;
          -  Immunocompromised at the time of enrollment. Known active malignancies.&#xD;
&#xD;
          -  Inability to comply with study requirements.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amadora</city>
        <zip>2720-276</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Angra do Heroismo</city>
        <zip>9700-049</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aveiro</city>
        <zip>3810-164</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3004-561</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Faro</city>
        <zip>8000-386</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Funchal</city>
        <zip>9000-177</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guimaraes</city>
        <zip>4835-044</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matosinhos</city>
        <zip>4450-021</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penafiel</city>
        <zip>4564-007</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Maria da Feira</city>
        <zip>4520-220</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setubal</city>
        <zip>2910-446</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Viana do Castelo</city>
        <zip>4904-858</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

